MIRA Pharmaceuticals (NASDAQ:MIRA) Earns Buy Rating from Analysts at Maxim Group

Maxim Group started coverage on shares of MIRA Pharmaceuticals (NASDAQ:MIRA) in a report released on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $3.50 price target on the stock.

Separately, Weiss Ratings lowered MIRA Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 20th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, MIRA Pharmaceuticals presently has an average rating of “Hold” and an average price target of $3.50.

MIRA Pharmaceuticals Price Performance

Shares of MIRA Pharmaceuticals stock opened at $0.83 on Thursday. MIRA Pharmaceuticals has a one year low of $0.60 and a one year high of $2.45. The firm has a market capitalization of $34.97 million, a price-to-earnings ratio of -0.67 and a beta of 1.52. The business has a 50-day simple moving average of $0.80 and a 200 day simple moving average of $0.95.

MIRA Pharmaceuticals (NASDAQ:MIRA) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.03) earnings per share for the quarter.

Hedge Funds Weigh In On MIRA Pharmaceuticals

A hedge fund recently bought a new position in MIRA Pharmaceuticals stock. BlackRock Inc. acquired a new position in shares of MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 244,622 shares of the company’s stock, valued at approximately $232,000. BlackRock Inc. owned approximately 0.58% of MIRA Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 35.16% of the stock is owned by institutional investors.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc is a clinical-stage pharmaceutical company focused on developing novel treatments for neurological and neuropsychiatric disorders. The company’s research is directed toward therapies for conditions with significant unmet medical needs, including anxiety, depression and chronic pain.

MIRA’s lead product candidate, MIRA-55, is an oral ketamine analog being developed for potential use in anxiety, depression and neuropathic pain. The company is evaluating the compound’s therapeutic potential and safety as it advances its development program.

MIRA Pharmaceuticals is headquartered in the United States and is led by Chief Executive Officer Erez Aminov.